By Steve Edelson
Staff writer

The start of VitaGen Inc.'s Phase II trial of its ELAD hepatic cell replacement therapy to treat liver failure makes it one of the few companies to have progressed this far in the clinic with a cell therapy product. Issues keeping the field from progressing rapidly include ethical as well as technological barriers, and the variable nature of cells.